Avatrombopag efficacy and side effects

AvatrombopagAvatrombopag is an oral medication indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled for surgery and for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an inadequate response to prior therapy.

Avatrombopag is an orally bioavailable small molecule TPO receptor agonist that stimulates megakaryocyte proliferation and differentiation of bone marrow progenitor cells, leading to increased platelet production. Avatrombopagdoes not compete with TPO for binding to TPO receptors, and has an additive effect on platelet production with TPO.

In patients with chronic liver disease, major side effects(occurring in at least 3% of cases)include fever, abdominal pain, nausea, headache, fatigue, and peripheral edema. The most commonly observed adverse reactions to thrombocytopenia in patients with chronic immune diseases (10% or more) include headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gum bleeding, petechiae, and nasopharyngitis. For patients with chronic liver disease who start taking this medicine 10 to 13 days before elective invasive testing or surgery, the patient should complete 5 days of dosage, and surgery should begin 5 to 8 days after the last dose. For patients with chronic immunity, the starting dose is 20 mg once daily, then adjust the dose or frequency of administration to maintain a platelet count greater than or equal to 50 x109/L, the maximum dose is 40mg. After starting treatment with avatrombopag, check the platelet count every week until the stable platelet count is greater than or equal to 50 x109/L, then check the platelet count monthly. When you stop taking avatrombopag, check your platelet count every week for at least 4 weeks. Avatrombopag is taken orally once daily for 5 consecutive daysdaily, take with food. If overdose occurs, platelet counts may increase excessively and lead to thrombosis or thromboembolic complications. Monitor patients and platelet counts closely. Treat thrombotic complications according to standard of care. It is recommended that nursing women receiving long-term DOPTELET treatment should not breastfeed during treatment and for at least 2 weeks after the last dose. If overdose occurs, platelet counts may increase excessively and lead to thrombosis or thromboembolic complications. Monitor patients and platelet counts closely. Treat thrombotic complications according to standard of care.

Laos and Bangladesh have generic drugs that are officially on the market. The specifications are 28 tablets. Each box is about 6100 to 9100. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.